SCHEMBL25275253

SCHEMBL25275253

CC(C)(C)C1N(c2ncnc3ncc(/C=N/N)cc23)CC12CCN(C(=O)O)CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25277206 0.89 — —
SCHEMBL25272219 0.89 JAK3 (0.32) —
SCHEMBL25270430 0.84 — —
SCHEMBL25276953 0.82 MEN1 (0.32) —
SCHEMBL25226496 0.73 KIT (0.43) —
SCHEMBL17925061 0.64 PANK3 (0.42) —
SCHEMBL26112897 0.63 — —
SCHEMBL16430906 0.61 PANK3 (0.32) —
SCHEMBL17925045 0.61 GPR119 (0.37) —
SCHEMBL25228458 0.61 KIT (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
Send feedback